Loyal Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
70
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$100M
- Investors
-
41
Loyal General Information
Description
Developer of veterinary drugs designed to improve dogs' health span and lifespan. The company's drugs delay the onset of age-related diseases like cancer, heart disease, and metabolic diseases, enabling pet owners to help their dogs live healthier and longer lives.
Contact Information
Website
www.loyal.comCorporate Office
- 548 Market Street
- Suite 26099
- San Francisco, CA 94104
- United States
Corporate Office
- 548 Market Street
- Suite 26099
- San Francisco, CA 94104
- United States
Loyal Timeline
Loyal Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 11-Feb-2026 | $100M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series B2) | 26-Feb-2025 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series B) | 21-Mar-2024 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A) | 23-Sep-2021 | Completed | Clinical Trials - General | |||
| 3. Seed Round | 23-Jun-2021 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 03-Jan-2020 | $4.86M | $4.86M | Completed | Clinical Trials - General | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - General |
Loyal Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-6 | ||||||||
| Series B-5 | ||||||||
| Series B-4 | ||||||||
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 5,801,553 | $0.000010 | 8% | $4.83 | $4.83 | 1x | $4.83 | 14.35% |
| Seed-4 | 219,701 | $0.000010 | 8% | $1.14 | $1.14 | 1x | $1.14 | 0.54% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Loyal Comparisons
Industry
Financing
Details
Loyal Competitors (4)
One of Loyal’s 4 competitors is Embark (Consumer Durables), a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Embark (Consumer Durables) | Venture Capital-Backed | Boston, MA | ||||
| Animal Bioscience | Venture Capital-Backed | Boston, MA | ||||
| Rejuvenate Bio | Venture Capital-Backed | San Diego, CA | ||||
| Unity Biotechnology | Formerly VC-backed | South San Francisco, CA |
Loyal Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Loyal Patents
Loyal Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024263787-A1 | Methods for measuring metabolic dysfunction or risk or presence of an age-associated disease | Inactive | 23-Jun-2023 | ||
| GB-202407588-D0 | Method of increasing lifespan in mammals | Pending | 27-Mar-2023 | ||
| GB-2630855-A | Method of increasing lifespan in mammals | Pending | 27-Mar-2023 | ||
| US-20250170113-A1 | Method of increasing lifespan in mammals | Pending | 27-Mar-2023 | ||
| WO-2024206499-A2 | Method of increasing lifespan in mammals | Inactive | 27-Mar-2023 | A61P3/04 |
Loyal Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Loyal Investors (41)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Baillie Gifford | Growth/Expansion | Minority | ||
| Invariantes Fund | Venture Capital | Minority | ||
| Profluent Ventures | Venture Capital | Minority | ||
| Age 1 | Venture Capital | Minority | ||
| Deep Checks | Venture Capital | Minority |
Loyal FAQs
-
When was Loyal founded?
Loyal was founded in 2019.
-
Where is Loyal headquartered?
Loyal is headquartered in San Francisco, CA.
-
What is the size of Loyal?
Loyal has 70 total employees.
-
What industry is Loyal in?
Loyal’s primary industry is Other Consumer Non-Durables.
-
Is Loyal a private or public company?
Loyal is a Private company.
-
What is the current valuation of Loyal?
The current valuation of Loyal is .
-
What is Loyal’s current revenue?
The current revenue for Loyal is .
-
How much funding has Loyal raised over time?
Loyal has raised $236M.
-
Who are Loyal’s investors?
Baillie Gifford, Invariantes Fund, Profluent Ventures, Age 1, and Deep Checks are 5 of 41 investors who have invested in Loyal.
-
Who are Loyal’s competitors?
Embark (Consumer Durables), Animal Bioscience, Rejuvenate Bio, and Unity Biotechnology are competitors of Loyal.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
